Dextroamphetamine - Pharmacokinetics
Research News and Information

Tuesday, November 24, 2009

Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.

30 Aug 2009 OBJECTIVE: To evaluate the pharmacokinetics of lisdexamfetamine dimesylate (LDX), a long-acting prodrug stimulant, and mixed amphetamine salts extended-release (MAS XR), alone or with omeprazole, a proton pump inhibitor (PPI). METHODS: This ... Read more...

The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.

30 Dec 2008 BACKGROUND: Lisdexamfetamine dimesylate (LDX) is a once-daily medication approved by the US Food and Drug Administration for the management of attention-deficit/hyperactivity disorder (ADHD) in children (aged 6-12 years) and adults. OBJECTIVE: This ... Read more...

Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.

15 Jul 2008 The objective of this study is to determine the safety, tolerability and abuse liability of single intravenous (i.v.) doses of lisdexamfetamine dimesylate (LDX) and immediate-release d-amphetamine sulphate in adult stimulant abusers compared with ... Read more...

Latest indexed articles for 'Dextroamphetamine - Pharmacokinetics'

These are the very latest articles for this heading:

• Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults. 30 Aug 2009
• The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. 30 Dec 2008
• Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. 15 Jul 2008
• Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder. 30 May 2008
• Lisdexamfetamine dimesylate for childhood ADHD. 29 Apr 2008
• Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study. 28 Feb 2008
• Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. 30 Dec 2007
• Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. 30 Dec 2007
• Differences in performance between Sprague-Dawley and Fischer 344 rats in positive reinforcement tasks. 4 Nov 2007
• The effect of stimulant treatment for ADHD on later substance abuse and the potential for medication misuse, abuse, and diversion. 30 Oct 2007
• Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. 22 Oct 2007
• Lisdexamfetamine dimesylate (Vyvanse) for ADHD. 14 Jul 2007
• New drugs: aliskiren hemifumarate, lisdexamfetamine dimesylate, and lapatinib. 29 Apr 2007
• Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. 3 Apr 2007
• Lisdexamfetamine. 30 Dec 2006
• In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI. 24 Dec 2006
• Sex differences in amphetamine-induced displacement of [(18)F]fallypride in striatal and extrastriatal regions: a PET study. 30 Aug 2006
• The acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance. 6 Jun 2006
• The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of d-methylphenidate and d-amphetamine. 16 Apr 2006
• Amphetamine- and scopolamine-induced locomotor activity following treatment with chlorphenvinphos or chlorphyriphos in rats. 30 Dec 2004

See a longer list of these articles.

Technical information about 'Dextroamphetamine'

Definition: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.

Chemical name: Benzeneethanamine, alpha-methyl-, (S)-

Registry Number: 51-64-9

Descriptor UI: D003913

Alternative terms: Dextroamphetamine; dextro-Amphetamine; dextro Amphetamine; Dexamphetamine; d-Amphetamine; d Amphetamine; Dexamfetamine; Oxydess; Vortech Brand of Dextroamphetamine Sulfate; Dextroamphetamine Sulfate; Sulfate, Dextroamphetamine; d-Amphetamine Sulfate; d Amphetamine Sulfate; Dextro-Amphetamine Sulfate; Dextro Amphetamine Sulfate; DextroStat; Shire Brand of Dextroamphetamine Sulfate; Curban; Pasadena Brand of Dextroamphetamine; Dexedrine; GlaxoSmithKline Brand of Dextroamphetamine Sulfate; Mallinckrodt Brand of Dextroamphetamine Sulfate; Celltech Brand of Dextroamphetamine Sulfate;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Dopamine Uptake Inhibitors; Central Nervous System Stimulants;

Tree Number: D02.092.471.683.152.110.200;

Online Note: use DEXTROAMPHETAMINE to search DEXTRO AMPHETAMINE 1966-76

History Note: 77; was DEXTRO AMPHETAMINE 1963-76